{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T15:24:30Z","timestamp":1768058670330,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,10]]},"DOI":"10.7759\/cureus.101227","type":"journal-article","created":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:42:56Z","timestamp":1768048976000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparative Study of the Efficacy of Ranolazine as Add-On Therapy With Metformin Versus Metformin Monotherapy on Glycaemic Control in Patients of Type 2 Diabetes Mellitus"],"prefix":"10.7759","author":[{"given":"Nidhi","family":"Kumari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amrendra K","family":"Arya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ved","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saajid","family":"Hameed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitesh","family":"Mishra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harihar","family":"Dikshit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26031094","article-title":"Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications","volume":"26","author":"M\u0142ynarska E","year":"2025","unstructured":"M\u0142ynarska E, Czarnik W, Dzie\u017ca N, et al.. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci. 2025, 26:10.3390\/ijms26031094","journal-title":"Int J Mol Sci"},{"key":"ref2","article-title":"IDF Diabetes Atlas, 10th edition","author":"Magliano DJ","year":"2021","unstructured":"Magliano DJ, Boyko EJ. IDF Diabetes Atlas, 10th edition. International Diabetes Federation, Brussels; 2021."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107843","article-title":"Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition","volume":"157","author":"Saeedi P","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, et al.. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019, 157:107843. 10.1016\/j.diabres.2019.107843","journal-title":"Diabetes Res Clin Pract"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2174\/1573403X1604201229115531","article-title":"Complications of the type 2 diabetes mellitus","volume":"16","author":"Farmaki P","year":"2020","unstructured":"Farmaki P, Damaskos C, Garmpis N, Garmpi A, Savvanis S, Diamantis E. Complications of the type 2 diabetes mellitus. Curr Cardiol Rev. 2020, 16:249-51. 10.2174\/1573403X1604201229115531","journal-title":"Curr Cardiol Rev"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2174\/1570161117666190405165151","article-title":"Macrovascular complications of type 2 diabetes mellitus","volume":"18","author":"Viigimaa M","year":"2020","unstructured":"Viigimaa M, Sachinidis A, Toumpourleka M, Koutsampasopoulos K, Alliksoo S, Titma T. Macrovascular complications of type 2 diabetes mellitus. Curr Vasc Pharmacol. 2020, 18:110-6. 10.2174\/1570161117666190405165151","journal-title":"Curr Vasc Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1177\/2042018820980225","article-title":"Should metformin remain the first-line therapy for treatment of type 2 diabetes?","volume":"12","author":"Baker C","year":"2021","unstructured":"Baker C, Retzik-Stahr C, Singh V, Plomondon R, Anderson V, Rasouli N. Should metformin remain the first-line therapy for treatment of type 2 diabetes?. Ther Adv Endocrinol Metab. 2021, 12:2042018820980225. 10.1177\/2042018820980225","journal-title":"Ther Adv Endocrinol Metab"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.7326\/M15-2650","article-title":"Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis","volume":"164","author":"Maruthur NM","year":"2016","unstructured":"Maruthur NM, Tseng E, Hutfless S, et al.. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med. 2016, 164:740-51. 10.7326\/M15-2650","journal-title":"Ann Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-137-1-200207020-00009","article-title":"Metformin: an update","volume":"137","author":"Kirpichnikov D","year":"2002","unstructured":"Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002, 137:25-33. 10.7326\/0003-4819-137-1-200207020-00009","journal-title":"Ann Intern Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/archinternmed.2009.20","article-title":"Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus","volume":"169","author":"Kooy A","year":"2009","unstructured":"Kooy A, de Jager J, Lehert P, Bets D, Wulffel\u00e9 MG, Donker AJ, Stehouwer CD. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Arch Intern Med. 2009, 169:616-25. 10.1001\/archinternmed.2009.20","journal-title":"Arch Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S38753","article-title":"Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated","volume":"7","author":"Irons BK","year":"2014","unstructured":"Irons BK, Minze MG. Drug treatment of type 2 diabetes mellitus in patients for whom metformin is contraindicated. Diabetes Metab Syndr Obes. 2014, 7:15-24. 10.2147\/DMSO.S38753","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1186\/s40545-022-00457-5","article-title":"Adherence to metformin in adults with type 2 diabetes: a combined method approach","volume":"15","author":"Syafhan NF","year":"2022","unstructured":"Syafhan NF, Donnelly R, Harper R, et al.. Adherence to metformin in adults with type 2 diabetes: a combined method approach. J Pharm Policy Pract. 2022, 15:61. 10.1186\/s40545-022-00457-5","journal-title":"J Pharm Policy Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2368","article-title":"Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm","volume":"40","author":"Abdul-Ghani M","year":"2017","unstructured":"Abdul-Ghani M, DeFronzo RA. Is it time to change the type 2 diabetes treatment paradigm? Yes! GLP-1 RAs should replace metformin in the type 2 diabetes algorithm. Diabetes Care. 2017, 40:1121-7. 10.2337\/dc16-2368","journal-title":"Diabetes Care"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.10.102","article-title":"Role of ranolazine in cardiovascular disease and diabetes: exploring beyond angina","volume":"227","author":"Banerjee K","year":"2017","unstructured":"Banerjee K, Ghosh RK, Kamatam S, Banerjee A, Gupta A. Role of ranolazine in cardiovascular disease and diabetes: exploring beyond angina. Int J Cardiol. 2017, 227:556-64. 10.1016\/j.ijcard.2016.10.102","journal-title":"Int J Cardiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1177\/1060028016631757","article-title":"Ranolazine and its effects on hemoglobin A1C","volume":"50","author":"Greiner L","year":"2016","unstructured":"Greiner L, Hurren K, Brenner M. Ranolazine and its effects on hemoglobin A1C. Ann Pharmacother. 2016, 50:410-5. 10.1177\/1060028016631757","journal-title":"Ann Pharmacother"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.06.003","article-title":"Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study","volume":"219","author":"Caminiti G","year":"2016","unstructured":"Caminiti G, Fossati C, Battaglia D, Massaro R, Rosano G, Volterrani M. Ranolazine improves insulin resistance in non-diabetic patients with coronary heart disease. A pilot study. Int J Cardiol. 2016, 219:127-9. 10.1016\/j.ijcard.2016.06.003","journal-title":"Int J Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/BF00877121","article-title":"Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease","volume":"8","author":"Hayashida W","year":"1994","unstructured":"Hayashida W, van Eyll C, Rousseau MF, Pouleur H. Effects of ranolazine on left ventricular regional diastolic function in patients with ischemic heart disease. Cardiovasc Drugs Ther. 1994, 8:741-7. 10.1007\/BF00877121","journal-title":"Cardiovasc Drugs Ther"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2012.12.002","article-title":"RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study","volume":"1","author":"Maier LS","year":"2013","unstructured":"Maier LS, Layug B, Karwatowska-Prokopczuk E, et al.. RAnoLazIne for the treatment of diastolic heart failure in patients with preserved ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail. 2013, 1:115-22. 10.1016\/j.jchf.2012.12.002","journal-title":"JACC Heart Fail"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/jgf2.600","article-title":"Sample size determination: a practical guide for health researchers","volume":"24","author":"Althubaiti A","year":"2023","unstructured":"Althubaiti A. Sample size determination: a practical guide for health researchers. J Gen Fam Med. 2023, 24:72-8. 10.1002\/jgf2.600","journal-title":"J Gen Fam Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2629","article-title":"Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes","volume":"38","author":"Eckel RH","year":"2015","unstructured":"Eckel RH, Henry RR, Yue P, et al.. Effect of ranolazine monotherapy on glycemic control in subjects with type 2 diabetes. Diabetes Care. 2015, 38:1189-96. 10.2337\/dc14-2629","journal-title":"Diabetes Care"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.18203\/2349-3259.ijct20232853","article-title":"The efficacy of ranolazine in improving glycemic parameters in patients with type 2 diabetes mellitus: a meta-analysis","volume":"10","author":"Dampil OA","year":"2023","unstructured":"Dampil OA, Luy SC, De Lara BJ, Rialyn R, Raquel TA. The efficacy of ranolazine in improving glycemic parameters in patients with type 2 diabetes mellitus: a meta-analysis. Int J Clin Trials. 2023, 10:325-32. 10.18203\/2349-3259.ijct20232853","journal-title":"Int J Clin Trials"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.2337\/dc09-2334","article-title":"Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome","volume":"33","author":"Chisholm JW","year":"2010","unstructured":"Chisholm JW, Goldfine AB, Dhalla AK, Braunwald E, Morrow DA, Karwatowska-Prokopczuk E, Belardinelli L. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care. 2010, 33:1163-8. 10.2337\/dc09-2334","journal-title":"Diabetes Care"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/4952447","article-title":"Ranolazine improves glycemic variability and endothelial function in patients with diabetes and chronic coronary syndromes: results from an experimental study","volume":"2021","author":"Nusca A","year":"2021","unstructured":"Nusca A, Bernardini F, Mangiacapra F, et al.. Ranolazine improves glycemic variability and endothelial function in patients with diabetes and chronic coronary syndromes: results from an experimental study. J Diabetes Res. 2021, 2021:4952447. 10.1155\/2021\/4952447","journal-title":"J Diabetes Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.02.011","article-title":"Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina)","volume":"61","author":"Kosiborod M","year":"2013","unstructured":"Kosiborod M, Arnold SV, Spertus JA, et al.. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 diabetes evaluation of ranolazine in subjects with chronic stable angina). J Am Coll Cardiol. 2013, 61:2038-45. 10.1016\/j.jacc.2013.02.011","journal-title":"J Am Coll Cardiol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/451482-comparative-study-of-the-efficacy-of-ranolazine-as-add-on-therapy-with-metformin-versus-metformin-monotherapy-on-glycaemic-control-in-patients-of-type-2-diabetes-mellitus","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T12:42:57Z","timestamp":1768048977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/451482-comparative-study-of-the-efficacy-of-ranolazine-as-add-on-therapy-with-metformin-versus-metformin-monotherapy-on-glycaemic-control-in-patients-of-type-2-diabetes-mellitus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,10]]},"references-count":23,"URL":"https:\/\/doi.org\/10.7759\/cureus.101227","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1,10]]}}}